Product Description
Mechanisms of Action: PLAUR Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Heidelberg Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: South Africa, Thailand, Uganda, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PROTECT-APT 1 | P2 |
Recruiting |
COVID-19 |
2025-03-01 |